Skip to Content

Eli Lilly & Company (LLY US)

LLY US$1,351.12

20 minute delayed

Today ▼ -2.29%
1 year return ▲ 28.73%
Volume 744,140
Div yield 0.50%
PE ratio 43.85
52 week range
850.65 1,475.25

14 days free access

Join Market Matters and get full access to all our Opinion + Action

Learn more

Performance

Advanced charting functionality with the ability to amend timeframes, chart type & indicator selection, powered by TradingView.

Share price activity

Displays share price activity. Volume = number of shares traded, Turnover = value of shares traded, VWAP = volume-weighted average price for the day, sourced from Morningstar.
Last (Price)
1,351.12
Change
▼ -31.63 (-2.29)
Bid / Ask
1,351.20 - 1,351.50
Volume
744,140
Turnover
939,296,056
Open
1,366.72
Day Range
1,341.47 - 1,381.99
VWAP
1,353.68
Prev Close
1,382.75
Last Trade
19/11 7:00pm
Displays useful ratios for the security, NB the pricing date used, sourced from Morningstar.
Ratios
Currency (Price/reporting): USD/USD
Exchange Rate: 1.0000
Price, volume and trading statistics for the security, sourced from Morningstar.
Price - closing or last bid 1,415.55
Price - 12 month high 1,475.25
Price - 12 month low 850.65
Pricing date 17 NOV 2026
Volume - avg. trading volume for the last ten days 3.18
Market capitalization 1,231,677.69
12 Month High price date 16 NOV 2026
12 Month Low price date 29 APR 2026
Volume - avg. trading volume for the last 3 months 2.58
Price - 1 Day % Change -1.13%
Price - 13 week price percent change 19.64%
Price - 26 week price percent change 40.86%
Price - 5 Day % Change -1.17%
Price - 52 week price percent change 38.55%
Price - YTD price percent change 31.10%
Price % Change Month To Date 12.61%
Earnings, dividends, cash flow and book value per share, sourced from Morningstar.
EPS excluding extraordinary items - most recent fiscal year 22.950
EPS excluding extraordinary items - trailing 12 month 30.810
EPS Normalized - most recent fiscal year 24.210
Revenue/share - most recent fiscal year 72.477
Revenue/share - trailing 12 month 96.571
Book value per share - most recent fiscal year 29.655
Book value per share - most recent quarter 45.187
Book value (tangible) per share - most recent fiscal year 15.774
Book value (tangible) per share - most recent quarter 13.816
Cash per share - most recent fiscal year 8.122
Cash per share - most recent quarter 5.481
Cash Flow per share - most recent fiscal year 27.695
Cash Flow per share - trailing 12 month 40.452
Dividend per share - most recent fiscal year 6.230
Dividends per share - trailing 12 month 6.920
EBITD per share - trailing 12 month 42.440
EPS Basic excluding extraordinary items - most recent fiscal year 23.000
EPS Basic excluding extraordinary items - trailing 12 month 30.850
EPS including extraordinary items - most recent fiscal year 23.000
EPS including extraordinary items - trailing 12 month 30.850
Free Cash Flow per share - trailing 12 month 19.280
Valuation multiples such as P/E, price to sales, price to book and enterprise value ratios, sourced from Morningstar.
P/E excluding extraordinary items, most recent fiscal year 44.88
P/E Normalized, most recent fiscal year 43.28
Price to sales - most recent fiscal year 14.32
Price to Tangible Book - most fiscal year 100.08
Price to Free Cash Flow per Share - most recent fiscal year 71.72
Price to Cash Flow per share - trailing 12 month 34.18
Price to Book - most recent fiscal year 30.60
P/E excluding extraordinary items high, trailing 12 months 54.38
P/E excluding extraordinary items low, trailing 12 months 33.20
Net Debt, LFI 44,618.00
Net Debt, LFY 35,235.00
Dividend Yield - 5 Year Average 0.75%
Dividend Yield - indicated annual dividend divided by closing price 0.48%
Current Dividend Yield - Common Stock Primary Issue, LTM 0.50%
Cash flow, liquidity and leverage measures, sourced from Morningstar.
Free Cash Flow - most recent fiscal year 14,057.00
LT debt/equity - most recent fiscal year 154.02%
Payout ratio - most recent fiscal year 27.15%
Total debt/total equity - most recent fiscal year 160.18%
LT debt/equity - most recent quarter 116.67%
Total debt/total equity - most recent quarter 122.92%
Free Cash Flow - trailing 12 month 17,262.30
Payout ratio - trailing 12 month 21.71%
Key income statement lines for the most recent fiscal year, in millions, sourced from Morningstar.
Revenue - most recent fiscal year 65,179.00
Revenue - trailing 12 month 86,462.00
EBITD - most recent fiscal year 27,728.00
EBITD - trailing 12 month 37,997.90
Earnings before taxes - most recent fiscal year 25,731.00
Earnings before taxes - trailing 12 month 34,769.20
Net Income available to common - most recent fiscal year 20,640.00
Net Income available to common - trailing 12 months 27,579.70
Earnings before taxes Normalized - most recent fiscal year 29,571.00
Net Income Available to Common, Normalized - most recent fiscal year 21,768.00
Earnings per Share, Normalized, Excluding Extraordinary Items, Avg. Diluted Shares Outstanding, TTM 31.95
Profitability margins for the most recent fiscal year, sourced from Morningstar.
Net Profit Margin % - 1st historical fiscal year 31.67%
Net Profit Margin % - trailing 12 month 31.90%
Operating margin - 1st historical fiscal year 45.56%
Operating margin - trailing 12 month 51.25%
Pretax margin - trailing 12 month 40.21%
Pretax margin - 1st historical fiscal year 39.48%
Operating Margin - 5 year average 33.93%
Pretax Margin - 5 year average 26.48%
Free Operating Cash Flow/Revenue, 5 Year Average 14.71%
Free Operating Cash Flow/Revenue, TTM 19.97%
Net Profit Margin - 5 year average 22.42%
Returns on average assets and equity for the fiscal year, the trailing 12 months and as 5 year averages, and net income and revenue per employee in whole currency, sourced from Morningstar.
Return on average assets - most recent fiscal year 20.79%
Return on average assets - trailing 12 month 21.74%
Return on average equity - most recent fiscal year 104.63%
Return on average equity - trailing 12 month 88.58%
Return on average assets - 5 year average 14.77%
Return on average equity - 5 year average 75.68%
Net Income/employee - most recent fiscal year 412,800.00
Revenue/employee - most recent fiscal year 1,303,580.00
Growth in revenue, earnings, dividends and book value over recent periods, sourced from Morningstar.
Revenue growth rate, 5 year 21.58%
EPS growth rate, 5 year 27.58%
Growth rate% - dividend, 3 year 15.24%
Revenue/share (5 yr growth) 21.93%
Growth rate% - Revenue, 3 year 31.69%
Growth rate% - EPS, 3 year 49.27%
Book value per share growth rate, 5 year 38.13%
Capital Spending growth rate, 5 year 39.84%
Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year CAGR 25.57%
Displays analyst’s forecasts for key measures. The estimates can be expanded to see the spread of the calls. Full lines = reported, and dotted lines are forward estimates. Click a measure to add or remove it from the chart, sourced from Morningstar.

Financial forecast (USD, millions except per share)

Actuals Estimates
2025 2026202720282029
Financial metrics can be plotted on the graph to see trends. Multiple metrics from multiple statements can be plotted against each other, sourced from Morningstar.

Financials (USD, millions)

Period end: DEC 21DEC 22DEC 23DEC 24DEC 25
Fiscal year: 20212022202320242025
Period length: 12 months12 months12 months12 months12 months
Displays all company announcements released by the company to the exchange, sourced from Morningstar.

Announcements

Announcements are available for ASX-listed companies only.

Opinion

Action

Business Summary

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

image description

Relevant suggested news and content from the site

Back to top